AAAswathy Alangode

Aswathy Alangode

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aswathy Alangode has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Role of Regulated Cell Death Pathways in Snakebite Envenomation: Mechanisms, Crosstalk, and Therapeutic Opportunities

    by Aswathy Alangode, Adithyan Rajasekhar, Jyotsna J. Sabu, Sanjay Krishna, Devika Anuja, Anushree Sreeja, Goutham Remesh, Adithya Kaladevi, Bipin G. Nair

    Snakebite envenomation causes severe tissue damage, often resulting in permanent disability with long-term complications like amputations and organ dysfunction. Current antivenoms, which are antibody-based, have lower tissue penetrability and limited efficacy in minimizing the local effects, highlighting the need for adjunct therapies. Emerging evidence indicates that venom-induced pathology is not restricted to direct cytotoxicity and necrosis; rather, it also involves multiple interconnected Regulated Cell Death (RCD) pathways, but their mechanistic interplay and therapeutic implications remain poorly understood. This review examines how venom toxins induce a cellular stress response characterized by oxidative stress, membrane disruption, and calcium overload, leading to the activation of interconnected regulated cell death (RCD) pathways, including apoptosis, ferroptosis, and pyroptosis, together with autophagy and mitophagy, which primarily function as cellular stress responses that modulate these forms of regulated cell death. We further discuss the crosstalk between these RCD pathways and emerging therapeutic approaches targeting these mechanisms. Understanding these interconnected RCD pathways may facilitate the development of adjunct therapies that complement antivenom, reduce snakebite-induced morbidity, and improve clinical outcomes.

  • Open Access

    Animal Venoms Targeting Cellular Mechanisms: Advances and Implications for Drug Discovery and Disease Therapy

    by Lucienne Mathai, Bipin G. Nair, Aswathy Alangode

    Animal venoms are complex biochemical systems composed of proteins, peptides, and small molecules with bioactivity. Traditionally regarded as toxic agents, venom components are increasingly recognized as valuable molecular libraries that can modulate cellular processes in human disease pathophysiology. This review highlights the translational potential of venom-derived molecules, with emphasis on clinically approved venom-derived drugs such as captopril, while also discussing their therapeutic potential for diseases such as cancer, autoimmunity, cardiovascular diseases, chronic pain, neuropsychiatric disorders, and infectious diseases. Special emphasis is given to the mechanisms by which these toxins modulate ion channels, enzymes, and receptor systems. Recent advances in venomics, harnessing proteomics, transcriptomics, and high-throughput screening, are also discussed, which can accelerate the clinical translation of venom-derived therapeutics. Key challenges related to assessing the immunogenicity of the venom-derived compounds, bioavailability, and safety have also been addressed alongside emerging strategies to overcome them. Collectively, these advances can provide a logical framework for developing novel therapeutics, bridging the gap between toxinology and drug discovery.


  • Prediction of protein–protein interaction sites between Russell’s viper PLA2 and the γ-phospholipase inhibitor PIP from the amino acid frequency distribution of a bio-panned peptide set

    by Karthika Rajan, Margaret Reick, Aswathy Alangode, Martin Reick

    We screened a random peptide phage display library using Russell’s viper venom phospholipase A2 (RV-PLA2) as bait. Sequence information from the resulting set of bio-panned heptapeptides was analyzed and mined to determine likely sites of interaction between two subunits of RV-PLA2 homo dimers and between RV-PLA2 and the γPLA2 inhibitor PIP from Malayopython reticulatus. This was accomplished in part by sequence alignment of the affinity-selected peptides with the sequences of RV-PLA2 and PIP. Because similarity scores calculated from sequence alignments proved inadequate to determine interaction interfaces accurately for RV-PLA2 dimers, we explored the use of amino acid frequency-based interactions scores (SFI/SFIN) for a more accurate prediction of protein–protein interaction sites. Heptamers with elevated SFI(N) scores were compared to interfaces of interaction observed in crystal structures of RV-PLA2 homodimers and to sites of interaction predicted by protein–protein docking between structures of RV-PLA2 and model of PIP. Segments with a high density of protein–protein contacts coincided with heptamer sequences exhibiting SFI and/or SFIN scores significantly above average, in both RV-PLA2 homodimers and in RV-PLA2 γPLI heteromeric structures. Elevated SFI and SFIN scores were associated with peptide function since the heptamers with some of the highest SFI and SFI(N) scores, LPGLPLS, GLPLSLQ and SLQNGLY constitute the known PLA2 inhibitor P-PB.I (LPGLPLSLQNGLY) while KLGRVDI, and WDGVYIR, constitute PIP-17 (LGRVDIHVWDGVYIRGR), IC50 for hsPLA2: 5.3 μM. A graph showing the alignment of maxima between SFI scores and average solvent accessibility (per heptamer) suggests that solvent accessibility is a major driver of both protein–protein interaction and phage selection. Insights We show by computational methods that in sets of small phage-displayed peptides of the same length selected for binding to the same target protein, amino acids contributing to binding at a particular position occur at higher frequencies than in random peptides. This position-specific selection of particular amino acids can be detected in the position-specific amino acid frequency distribution of that set of selected peptides. Therefore, when this position-specific amino acid frequency is mapped back onto a particular amino acid sequence of the same length, the sum of these frequencies can function as a measure of enrichment of selected amino acids.

  • Open Access

    The Need for Next-Generation Antivenom for Snakebite Envenomation in India

    by Muralidharan Vanuopadath, Karthika Rajan, Aswathy Alangode, Sudarslal Sadasivan Nair, Bipin Gopalakrishnan Nair

    The limitations posed by currently available antivenoms have emphasized the need for alternative treatments to counteract snakebite envenomation. Even though exact epidemiological data are lacking, reports have indicated that most global snakebite deaths are reported in India. Among the many problems associated with snakebite envenomation, issues related to the availability of safer and more efficient antivenoms are of primary concern. Since India has the highest number of global snakebite deaths, efforts should be made to reduce the burden associated with snakebite envenoming. Alternative methods, including aptamers, camel antivenoms, phage display techniques for generating high-affinity antibodies and antibody fragments, small-molecule inhibitors, and natural products, are currently being investigated for their effectiveness. These alternative methods have shown promise in vitro, but their in vivo effectiveness should also be evaluated. In this review, the issues associated with Indian polyvalent antivenoms in neutralizing venom components from geographically distant species are discussed in detail. In a nutshell, this review gives an overview of the current drawbacks of using animal-derived antivenoms and several alternative strategies that are currently being widely explored.